DEF: IDEXX Reports Strong 2025 Growth, Announces CEO Transition

Sentiment:

Proxy Statement 27 March 2026 4:00 PM

📋All filings for Idexx Laboratories INC /DE

IDEXX Laboratories achieved solid 2025 financial results with 10% revenue growth and 23% diluted EPS increase, alongside a planned CEO transition and significant innovation advancements.

Better than expectedAchieved 10% reported and organic revenue growth, exceeding the 2025 target goal of 8.1% for the annual performance-based cash bonus plan.Reported diluted EPS increased to $13.08 per share, a 23% reported and 14% annual comparable EPS growth, surpassing the target of $12.25 for the annual performance-based cash bonus plan.Operating profit reached $1,320.6 million (adjusted for bonus plan), exceeding the target of $1,307.7 million.Return on Invested Capital (ROIC) was 48.3% (adjusted for bonus plan), exceeding the target of 47.8%.The financial performance factor for the annual cash bonus plan was 132% of target, and the non-financial performance factor was 153% of target, leading to an overall payout of 140% of target for non-CEO NEOs and 173% for the CEO.

Summary

IDEXX delivered 10% reported and organic revenue growth in 2025.
Companion Animal Group (CAG) Diagnostics recurring revenue grew 9% reported and 8% organically.
Reported diluted earnings per share (EPS) increased to $13.08, representing 23% reported and 14% annual comparable EPS growth.
The company achieved strong comparable operating margin improvements.
More than 22,000 premium instruments were placed, including over 6,000 IDEXX inVue Dx cellular analyzers, contributing to a 12% growth in the premium instrument installed base.
Cloud-based practice management systems (ezyVet and Neo) saw double-digit installed-base growth, surpassing 10,000 locations.
IDEXX expanded its commercial presence in Australia, Germany, and the United Kingdom.
Customer retention in the key CAG Diagnostics business remained in the high nineties.
The IDEXX Cancer Dx canine lymphoma screening test achieved broad adoption with over 5,500 customers in North America.
Jonathan (Jay) Mazelsky will step down as President and CEO on May 12, 2026, with Michael G. Erickson, PhD, assuming the role.
Jay Mazelsky will serve as Executive Chair of the Board for a one-year period until his retirement in May 2027.
The Board proposes amending the Certificate of Incorporation to declassify the Board over a three-year period, starting at the 2027 Annual Meeting.
The Board proposes amending the Certificate of Incorporation to provide shareholders owning at least 25% of capital stock the right to call a special meeting.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong performance report, with significant financial growth and strategic advancements, particularly in innovation and market expansion, despite some macroeconomic headwinds. The planned CEO transition appears well-managed, and proposed governance changes enhance shareholder rights.

Positives

Achieved 10% reported and organic revenue growth in 2025.
Reported diluted EPS increased to $13.08 per share, a 23% reported and 14% annual comparable EPS growth.
Delivered strong comparable operating margin improvements.
More than 22,000 premium instrument placements, including over 6,000 IDEXX inVue Dx cellular analyzers, driving 12% growth in the premium instrument installed base.
Cloud-native PIMS surpassed 10,000 locations with double-digit installed-base growth.
Successfully completed three international commercial expansions in Australia, Germany, and the United Kingdom, while also expanding U.S.-based field resources.
Maintained customer retention in the high nineties within the key CAG Diagnostics business.
Achieved broad adoption of IDEXX Cancer Dx canine lymphoma screening tests with over 5,500 customers in North America.
Launched IDEXX Cancer Dx, a first-of-its-kind diagnostic panel for early detection of canine lymphoma.
Expanded the inVue Dx Cellular Analyzer platform to include fine needle aspirate (FNA) cytology for mast cell tumor detection.
Introduced the Catalyst Cortisol Test, the third menu expansion for the Catalyst platform in approximately a year.
Finalized development and launched the ImageVue DR50 Plus Digital Imaging System in January 2026, reducing radiation exposure by up to 60%.
Achieved an employee net promoter score above the 90th percentile for all employers.
Signed a third virtual power purchase agreement (VPPA), the first in Europe, expected to cover 100% of North American and European electricity consumption when online.
Transitioned approximately 42% of the commercial fleet to hybrid and electric vehicle models by the end of 2025.
Generated $1.2 billion in operating cash flow, a 27% increase over 2024.
Delivered $1.1 billion in free cash flow, a 31% increase over 2024, representing 100% of net income.
Achieved a 50.2% Return on Invested Capital (ROIC) in 2025.

Negatives

Experienced a 2% decline in U.S. same-store clinical visit levels in 2025.

Risks

The adverse impact, and the duration, of macroeconomic and geopolitical events, conditions, and uncertainties.
General economic uncertainty.
Tariff and trade policies of the United States and other countries.
The company's ability to successfully execute its strategy.
Supply chain challenges.
The development of innovative new technologies.
The regulatory environment in the United States and in other countries and the company's ability to obtain necessary regulatory approvals for new products or services within expected timeframes, or at all.
The company's ability to attract, develop, and retain highly capable and skilled employees and leaders.
Increasing global cybersecurity vulnerabilities and threats.
Risks related to generative AI, including responsible and ethical use, protection of intellectual property and confidential information, compliance with data privacy obligations, and management of suppliers providing or using generative AI functionality.

Future Outlook

IDEXX remains committed to enhancing pet, people, and livestock health and well-being, confident in its ability to build on momentum and deliver diagnostic and digital tools. The company targets an estimated $45+ billion total global addressable companion animal diagnostics revenue opportunity and aims for long-term EPS growth potential of 15%+, driven by 10%+ revenue growth, 50-100 bps operating margin expansion, and 1-2% capital allocation leverage. Plans include expanding the IDEXX Cancer Dx panel to cover a majority of canine cancer cases by 2028 and broad availability of inVue Dx FNA cytology throughout 2026.

Management Comments

"In many ways, 2025 was a defining year for IDEXX. We successfully scaled multiple transformative innovations, expanded our commercial presence in key international regions and made meaningful strategic progress toward our long-term potential." Jonathan (Jay) Mazelsky, President and CEO.
"With momentum from these achievements, the strength of our teams and a thoughtful, orderly upcoming planned CEO transition underway, we enter 2026 with confidence in our strategy and our ability to realize the opportunities ahead for many years to come." Jonathan (Jay) Mazelsky, President and CEO.
"It has been a privilege to lead IDEXX since 2019, and I am confident IDEXX is well-positioned for sustained growth and success." Jonathan (Jay) Mazelsky, President and CEO.
"Having worked closely with Mike for more than a decade, I know firsthand his deep knowledge of our business and believe he is the right person to lead IDEXX into the future." Jonathan (Jay) Mazelsky, President and CEO.
"The Board thanks Jay for his outstanding leadership and dedicated service to IDEXX. During his tenure as CEO, IDEXX advanced its innovation-driven growth strategy and expanded its offerings globally. As a result, IDEXX is poised for continued success well into the future." Lawrence D. Kingsley, Independent Non-Executive Board Chair.
"We look forward to continuing to work with Jay in his capacity as Executive Chair and wish him all the best in his retirement in May 2027." Lawrence D. Kingsley, Independent Non-Executive Board Chair.
"The Board is highly confident that Dr. Erickson is uniquely well-situated to lead IDEXX forward and continue advancing our innovation-driven strategy to create long-term value for our shareholders and other stakeholders." Lawrence D. Kingsley, Independent Non-Executive Board Chair.

Industry Context

StockSavvy.ai notes that IDEXX's strong 2025 performance, particularly in companion animal diagnostics and cloud-based practice management systems, demonstrates resilience in a veterinary market experiencing a 2% decline in U.S. same-store clinical visits. The company's aggressive innovation roadmap, including early cancer detection and AI-powered imaging, positions it to capture a significant share of the estimated $45+ billion global addressable market, aligning with broader industry trends towards advanced diagnostics and digital transformation in pet healthcare.

Comparison to Industry Standards

IDEXX delivered a compound annual total shareholder return (TSR) of 18% over three years, 6% over five years, and 25% over ten years ending December 31, 2025.
IDEXX's TSR surpassed the S&P 500 Healthcare Index for the 1-year, 3-year, and 10-year periods ending December 31, 2025.
FactSet data indicates over 50% of S&P 500 companies that provide a shareholder right to call a special meeting have set the ownership threshold at 25% or higher, with 35% of S&P 500 companies setting this threshold at 25%, compared to only about 16% adopting a 10% threshold.

Management Changes

Role	Previous Person	New Person	Effective Date	Reason
President and CEO	Jonathan J. Mazelsky	Michael G. Erickson, PhD	May 12, 2026	Planned retirement and succession.
Executive Chair of the Board	NA	Jonathan J. Mazelsky	May 12, 2026	Transition role to facilitate smooth CEO succession until retirement.
Director	M. Anne Szostak	NA	May 2026	Retirement from the Board after nearly 14 years of service.
Director	NA	Michael G. Erickson, PhD	May 12, 2026	Appointment in connection with assuming CEO role.
Executive Vice President, Chief Financial Officer and Treasurer	Brian P. McKeon	Andrew Emerson	March 1, 2025	Mr. McKeon stepped down and retired in June 2025.
Executive Vice President, Global CAG Commercial	NA	George J. Fennell	January 2025	Promotion to lead global commercial sales, professional services and field support teams.
Executive Vice President, Global Strategy and Commercial	NA	Tina Hunt, PhD	January 2025	Promotion to lead global commercial, marketing, medical affairs, corporate development, and strategy and advanced analytics functions.
Executive Vice President and General Manager, CAG Diagnostics Business Unit	Michael J. Lane (previously Global Reference Laboratories, Diagnostic Solutions and Information Technology)	Michael J. Lane	March 2026	Reorganization of responsibilities.
Executive Vice President and General Manager, Veterinary Software, Diagnostic Imaging and Telemedicine, Corporate Accounts and Customer Experience	NA	Michael Schreck	March 2026	Reorganization of responsibilities.
Executive Vice President and Chief Technology Officer, R&D, Global Operations, Information Technology and Information Security	Martin Smith, PhD (previously Global Operations and R&D)	Martin Smith, PhD	March 2026	Reorganization of responsibilities.
Executive Vice President, General Counsel and Corporate Secretary	NA	Sharon E. Underberg	February 2022	Promotion.

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Board Structure	Board proposes amending Certificate of Incorporation to declassify the Board over a three-year period, starting at the 2027 Annual Meeting and completing by the 2029 Annual Meeting.	Upon shareholder approval and filing (phased in 2027-2029)	Enhances shareholder rights by moving to annual director elections, increasing accountability.
Shareholder Rights	Board proposes amending Certificate of Incorporation to provide shareholders owning at least 25% of outstanding capital stock continuously for at least one year the right to call a special meeting.	Upon shareholder approval and filing	Significantly enhances shareholder rights, balancing influence with protection against narrow interests.
Board Leadership	Transition from Independent Non-Executive Board Chair to an independent Lead Director, with the outgoing CEO (Jay Mazelsky) serving as Executive Chair for one year.	May 12, 2026	Aims to ensure a smooth CEO transition while maintaining independent board oversight.
Board Composition	Recruitment and onboarding of two new independent Directors, Joseph L. (Jay) Hooley and Karen Peacock, in 2025.	2025	Strengthens Board effectiveness by adding diverse experiences, skills, and perspectives, demonstrating commitment to refreshment.
Committee Responsibilities	Compensation and Talent Committee assumed responsibility for reviewing succession plans for non-CEO executive officers.	December 2025	Centralizes oversight of executive talent development and succession planning within the Compensation and Talent Committee.
Risk Oversight	Audit Committee oversees cybersecurity risk management, and the full Board oversees AI-related strategies and governance processes.	Ongoing	Ensures dedicated oversight of critical and evolving technological risks.
Executive Compensation Policy	Maintains a clawback policy that complies with and exceeds Nasdaq and SEC requirements, allowing for recovery of erroneously awarded incentive-based compensation.	Ongoing	Reinforces accountability and aligns executive pay with accurate financial performance.
Shareholder Engagement	Regular year-round engagement with shareholders, including meetings with institutional investors and an annual Investor Day.	Ongoing	Fosters transparency and allows the Board to actively listen to shareholder perspectives and concerns.

Legal Proceedings

A now-concluded litigation matter resulted in a reversal of an $8.6 million accrual in 2025, which positively impacted financial results.

Related Party Transactions

Sam Samad, an independent director, is Executive Vice President and Chief Financial Officer of Quest Diagnostics Incorporated, which provides remote route freight services to IDEXX.
IDEXX paid Quest Diagnostics approximately $0.8 million in 2025 for these services.
The Board and Governance and Corporate Responsibility Committee concluded these 'Quest Transactions' did not affect Mr. Samad's independence, as they were on arms-length terms, in the ordinary course of business, and Mr. Samad did not participate in negotiations.

Stakeholder Impact

Shareholders: Positive impact from strong financial performance, increased EPS, robust innovation pipeline, and enhanced corporate governance (board declassification, special meeting right). Potential for long-term value creation.
Employees: Positive impact from strong employee net promoter score, expanded learning and development offerings, new employee-led communities, expanded parental leave policy, and sustained low voluntary turnover rates.
Customers (Veterinarians/Pet Owners): Positive impact from new diagnostic solutions (IDEXX Cancer Dx, inVue Dx, Catalyst Cortisol Test, ImageVue DR50 Plus), cloud-based practice management systems (ezyVet, Neo), and pet-owner engagement software (Vello), aiming to improve productivity, medical outcomes, and care protocols. High customer retention (high nineties) indicates satisfaction.
Environment: Positive impact from commitment to 100% renewable electricity by 2030, 37.8% Scope 1 and 2 GHG emissions reduction by 2030, signing a European VPPA, increasing sea shipments to Asia Pacific, and transitioning commercial fleet to hybrid/electric vehicles (42% by end of 2025).

Next Steps

The 2026 Annual Meeting of Shareholders will be held on May 12, 2026.
Jonathan (Jay) Mazelsky will step down as President and CEO and assume the Executive Chair role on May 12, 2026.
Michael G. Erickson, PhD, will assume the President and CEO role on May 12, 2026.
M. Anne Szostak will retire from the Board in May 2026.
Broad availability of inVue Dx FNA cytology is expanding throughout 2026.
The IDEXX Cancer Dx panel is planned for launch in European reference laboratories in Q1 2026.
The IDEXX Cancer Dx panel will be expanded to add mast cell tumor detection mid-year 2026 in the U.S. and Canada.
IDEXX plans to expand the IDEXX Cancer Dx panel to address the majority of canine cancer cases by 2028.
The Board declassification will be phased in over a three-year period, culminating in the annual election of all directors by the 2029 Annual Meeting.
Amendments to the Certificate of Incorporation and By-Laws will be implemented to provide shareholders owning 25% of capital stock the right to call a special meeting.
The parental leave policy will be expanded to cover eligible employees in Australia, New Zealand, and the United Kingdom in 2026.

Key Dates

Date	Description
1973	Bruce L. Claflin began various senior management and executive positions at IBM.
1984	Daniel M. Junius joined Nashua Corporation.
1987	Stuart M. Essig, PhD, began as Managing Director, M&A, specializing in the medical device, pharmaceutical and biotechnology sectors at Goldman, Sachs and Co.
1988	Jonathan J. Mazelsky began various roles in finance, marketing and business planning at Hewlett Packard.
1988	Joseph L. (Jay) Hooley became President and Chief Executive Officer of National Financial Data Services.
1990	Joseph L. (Jay) Hooley became President and Chief Executive Officer of Boston Financial Data Services.
1991	M. Anne Szostak became Board Chair, President and Chief Executive Officer of Fleet-Maine.
1995	Bruce L. Claflin became Vice President and General Manager, PC Business Unit at Digital Equipment Corporation.
1996	Daniel M. Junius became Vice President and Chief Financial Officer at Nashua Corporation.
1996	Tina Hunt, PhD, joined Woodard Curran.
1997	Stuart M. Essig, PhD, became Chief Executive Officer of Integra LifeSciences Holdings Corporation.
1997	Bruce L. Claflin became Senior Vice President, Sales and Marketing at Digital Equipment Corporation.
1997	Michael J. Lane joined IDEXX.
1997	Jonathan J. Mazelsky became General Manager, Medical Consumables Business Unit at Agilent Technologies.
1998	Daniel M. Junius became Senior Vice President and Chief Financial Officer at New England Business Service, Inc.
1998	Bruce L. Claflin became President and Chief Operating Officer at 3Com Corporation.
1998	M. Anne Szostak became Corporate Executive Vice President and Chief Human Resources Officer at FleetBoston Financial Group.
1999	Michael P. Johnson began his career at Abbott Laboratories, Inc.
2000	Jonathan J. Mazelsky became Executive in Charge, Agilent Healthcare Solutions Group divestiture.
2001	Bruce L. Claflin became President and Chief Executive Officer of 3Com Corporation.
2001	M. Anne Szostak became Board Chair and Chief Executive Officer of Fleet Bank-Rhode Island.
2001	Jonathan J. Mazelsky began various roles of increasing responsibility at Philips Healthcare.
2002	Daniel M. Junius became Executive Vice President and Chief Financial Officer at New England Business Service, Inc.
2002	Sophie V. Vandebroek, PhD, became Chief Engineer at Xerox Corporation.
2002	Karen Peacock began senior roles of increasing responsibility at Intuit Inc.
2003	Michael G. Erickson, PhD, began roles of increasing responsibility at McKinsey & Company.
2003	George J. Fennell began as head of marketing for the companion animal business at Pfizer Animal Health.
2004	M. Anne Szostak founded Szostak Partners.
2004	Lawrence D. Kingsley became Chief Operating Officer at IDEX Corporation.
2004	Karen Peacock became Senior Vice President and General Manager, Salted Snacks at Kraft Foods, Inc.
2005	Daniel M. Junius became Senior Vice President and Chief Financial Officer at ImmunoGen, Inc.
2005	Lawrence D. Kingsley became Chief Executive Officer of IDEX Corporation.
2006	Tina Hunt, PhD, joined IDEXX.
2006	Sophie V. Vandebroek, PhD, became Chief Technology Officer and Corporate Vice President at Xerox Corporation.
2006	Martin Smith, PhD, began various leadership positions at Pall Corporation.
2008	Joseph L. (Jay) Hooley became President and Chief Operating Officer at State Street Corporation.
2009	Daniel M. Junius became President and Chief Executive Officer of ImmunoGen, Inc.
2009	Michael J. Lane became Senior Vice President and Chief Financial Officer, Pharmaceutical Segment at Cardinal Health, Inc.
2010	Jonathan J. Mazelsky became Senior Vice President and General Manager, Computed Tomography, Nuclear Medicine and Radiation Therapy Planning at Philips Healthcare.
2010	Joseph L. (Jay) Hooley became Chief Executive Officer of State Street Corporation.
2010	Stuart M. Essig, PhD, became Senior Advisor at TowerBrook Capital Partners.
2011	Michael G. Erickson, PhD, joined IDEXX.
2011	George J. Fennell joined IDEXX.
2011	Lawrence D. Kingsley became Chief Executive Officer of Pall Corporation.
2011	Joseph L. (Jay) Hooley became Board Chair of State Street Corporation.
2012	Jonathan J. Mazelsky became Executive Vice President at IDEXX.
2012	Stuart M. Essig, PhD, became Non-Executive Chair of Board of Directors at Integra LifeSciences Holdings Corporation.
2012	Stuart M. Essig, PhD, became Managing Director at Prettybrook Partners LLC.
2013	Stuart M. Essig, PhD, became Venture Partner at Wellington Partners Advisory AG.
2014	Daniel M. Junius joined IDEXX Board.
2014	Karen Peacock became General Manager, Employee Management Solutions division at Intuit Inc.
2015	Bruce L. Claflin joined IDEXX Board.
2015	Andrew Emerson joined IDEXX.
2016	Lawrence D. Kingsley joined IDEXX Board.
2016	SediVue Dx Urine Sediment Analyzer launched.
2017	Stuart M. Essig, PhD, joined IDEXX Board.
2017	Karen Peacock became Chief Operating Officer at Intercom, Inc.
2017	Sam Samad became Senior Vice President and Chief Financial Officer at Illumina, Inc.
2018	Sophie V. Vandebroek, PhD, became Chief Operating Officer, IBM Research.
2019	Jonathan J. Mazelsky became President and Chief Executive Officer of IDEXX.
2019	Sam Samad joined IDEXX Board.
2019	Sophie V. Vandebroek, PhD, became Inaugural Visiting Scholar at Massachusetts Institute of Technology School of Engineering.
2020	Karen Peacock became Chief Executive Officer of Intercom, Inc.
2020	Martin Smith, PhD, became Vice President and Chief Technology Officer of Cytiva.
2020	Michael Schreck joined IDEXX.
2021	ProCyte One Hematology Analyzer launched.
2021	Martin Smith, PhD, joined IDEXX.
2022	Michael P. Johnson joined IDEXX.
2022	Sam Samad became Executive Vice President and Chief Financial Officer at Quest Diagnostics Incorporated.
2023	Irene Chang Britt joined IDEXX Board.
2024	Vello Software launched in North America.
2024-12-01	IDEXX inVue Dx Cellular Analyzer launched.
2025-01-01	Joseph L. (Jay) Hooley joined IDEXX Board in July.
2025-01-01	Karen Peacock joined IDEXX Board in October.
2025-01-01	IDEXX Cancer Dx panel launched in U.S. and Canada in March.
2025-01-01	Controlled rollout of inVue Dx FNA cytology for mast cell tumor detection in late 2025 in the U.S.
2025-01-01	Catalyst Cortisol Test introduced.
2025-01-01	ImageVue DR50 Plus Digital Imaging System underwent final development.
2025-01-01	IDEXX achieved 10% reported and organic revenue growth.
2025-01-01	IDEXX achieved 23% reported and 14% annual comparable EPS growth.
2025-01-01	IDEXX delivered $1.2 billion in operating cash flow.
2025-01-01	IDEXX delivered $1.1 billion in free cash flow.
2025-01-01	IDEXX achieved 50.2% ROIC.
2025-01-01	IDEXX expanded U.S. CAG field-based resources.
2025-01-01	IDEXX paid Quest Diagnostics approximately $0.8 million for remote route freight services.
2025-01-01	Brian P. McKeon retired from IDEXX in June.
2025-01-01	Anne Szostak will retire from the Board in May.
2025-01-01	Compensation and Talent Committee assigned responsibility for non-CEO executive officer succession to itself in December.
2025-12-31	Fiscal year end for 2025.
2026-01-01	ImageVue DR50 Plus Digital Imaging System launched.
2026-01-13	Mr. Mazelsky's planned retirement and CEO transition announced via Form 8-K.
2026-02-14	First installment vesting date for 2025 RSU grants.
2026-03-08	Stock ownership information as of this date.
2026-03-16	Record date for 2026 Annual Meeting.
2026-03-27	Proxy Statement and 2025 Annual Report on Form 10-K made available to shareholders.
2026-05-12	2026 Annual Meeting of Shareholders date and time (10:00 a.m. Eastern Time).
2026-05-12	Jay Mazelsky to step down as President and CEO, Michael G. Erickson, PhD, to assume role.
2026-05-12	Jay Mazelsky to serve as Executive Chair of the Board for one year.
2026-05-12	Anne Szostak to retire from the Board.
2026-05-12	Michael G. Erickson, PhD, to join the Board as a Class II Director.
2026-06-01	Planned mid-year launch of expanded IDEXX Cancer Dx panel to add mast cell tumor detection in U.S. and Canada.
2026-11-27	Deadline for shareholder proposals under Rule 14a-8 for 2027 Annual Meeting.
2027-01-12	Earliest date for written notice of other nominations or business for 2027 Annual Meeting (assuming meeting between April 22 and July 11, 2027).
2027-02-11	Latest date for written notice of other nominations or business for 2027 Annual Meeting (assuming meeting between April 22 and July 11, 2027).
2027-02-14	First vesting date for Mr. Mazelsky's 2026 annual equity award.
2027-03-15	Latest payment date for Mr. Mazelsky's FY 2026 Bonus if Involuntary Termination occurs after Transition Date and prior to Retirement Date.
2027-05-01	Jay Mazelsky's retirement from the Company and the Board.
2027-05-01	Class I Directors standing for election at the 2027 Annual Meeting would be elected for one-year terms expiring at the 2028 Annual Meeting.
2027-10-28	Earliest date for proxy access nominations for 2027 Annual Meeting.
2027-11-27	Latest date for proxy access nominations for 2027 Annual Meeting.
2028-05-01	Class I and Class III Directors standing for election at the 2028 Annual Meeting would be elected for one-year terms expiring at the 2029 Annual Meeting.
2028-05-01	IDEXX plans to expand the IDEXX Cancer Dx panel to be capable of addressing the majority of canine cancer cases by this year.
2029-05-01	All Directors would stand for election annually, and the Board would no longer be classified.

Recommendation

strong buy

The filing details exceptional 2025 financial performance, including double-digit revenue and EPS growth, strong operating margins, and robust cash flow generation, all exceeding internal targets. Strategic advancements in innovation, market expansion, and customer engagement are significant. The well-managed CEO transition and proposed corporate governance enhancements further strengthen the company's long-term outlook. Despite a slight decline in U.S. clinical visits, the business model demonstrated resilience. These factors, combined with a clear vision for future growth in a large addressable market, indicate a strong investment opportunity.

Keywords

IDEXX Laboratories, SEC Filing, DEF 14A, Proxy Statement, Financial Performance, Revenue Growth, EPS Growth, Companion Animal Group, CAG Diagnostics, Veterinary Diagnostics, Pet Healthcare, Innovation, CEO Transition, Corporate Governance, Board Declassification, Special Shareholder Meeting, Cybersecurity, AI, Sustainability, Executive Compensation, Stock Options, RSUs, PSUs, Animal Health, Medical Devices, Software-as-a-Service, SaaS, Practice Management Systems, PIMS, Cancer Detection, Canine Lymphoma, Mast Cell Tumors, Digital Imaging, Catalyst Platform, VetConnect PLUS, Vello Software, Shareholder Rights

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.